ARTICLE
10 December 2025

Flawed Expert Evidence Can Limit Patent Damages To Nominal Amounts

LD
Lerner David

Contributor

For the past five decades, Lerner David has thrived as an intellectual property (IP) boutique dealing with all aspects of IP. IP is not just our specialty; it is our passion and purpose. We assist a diverse client base, protecting ground-breaking technologies and safeguarding some of the world's leading brands. And we fight for our clients' rights before the courts and administrative tribunals of the world. Lerner David stands at the ready to help innovators protect and bring tomorrow's emerging technologies to life today.
In Rex Medical, LP v. Intuitive Surgical, Inc., Nos. 2024-1072, 2024-1125 (Fed. Cir. Oct. 2, 2025), the Federal Circuit held that the district court did not abuse its discretion...
United States Intellectual Property
Lerner David are most popular:
  • within Intellectual Property topic(s)

In Rex Medical, LP v. Intuitive Surgical, Inc., Nos. 2024-1072, 2024-1125 (Fed. Cir. Oct. 2, 2025), the Federal Circuit held that the district court did not abuse its discretion when reducing the jury's $10 million damages award to a nominal $1. The Court reasoned that Rex Medical failed to provide enough evidence to establish a reasonable royalty calculation. The case involved Rex Medical's claim that Intuitive Surgical's staplers infringed two of its patents. The Federal Circuit found the methodology of the plaintiff's damages expert flawed, as the methodology attributed a lump-sum license payment made for a patent portfolio to only the patent-in-suit, without determining the extent to which the other patents in the portfolio contributed to the lump-sum payment. The Federal Circuit further determined that lay testimony from Rex's president also failed to allocate value among the patents in the portfolio, compelling the jury to guess at the damages. Despite evidence of over $600 million in total product sales for Intuitive Surgical's staplers, no information was provided to establish how much of those sales could be attributed to the patented innovations. The Federal Circuit thus concluded that, without sufficient evidence for a royalty rate calculation, the reduction to nominal damages was proper.

Edited by April Capati and Craig Drachtman.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More